新里程(002219) - 2023 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2023 was ¥900,351,136.03, representing an increase of 11.09% compared to ¥805,193,959.15 in the same period last year[11] - The net profit attributable to shareholders for Q3 2023 was a loss of ¥23,586,465.36, a decrease of 137.87% from a profit of ¥61,844,075.76 in the previous year[11] - The net profit attributable to shareholders after deducting non-recurring gains and losses was a loss of ¥19,491,827.90, down 222.60% from a profit of ¥15,462,621.60 in the same period last year[11] - The basic earnings per share for Q3 2023 was -¥0.0072, a decrease of 137.70% from ¥0.0189 in the same period last year[11] - Net profit for the period was ¥36,231,423.01, a decrease of 70.2% from ¥121,720,386.64 in the same period last year[38] - Total comprehensive income for the period attributable to the parent company was CNY 33,418,091.37, compared to CNY 112,659,527.56 in the previous period[41] - Basic and diluted earnings per share for the period were both CNY 0.0100, down from CNY 0.0345 in the previous period[41] Assets and Liabilities - The total assets at the end of the reporting period were ¥6,159,617,321.34, an increase of 9.09% from ¥5,642,118,964.71 at the end of the previous year[11] - Current liabilities totaled ¥3,078,161,844.35, down 7.5% from ¥3,327,031,224.88 in the previous period[34] - Non-current liabilities rose to ¥925,970,366.23, an increase of 67.2% from ¥554,103,266.66 in the prior year[34] - The total equity attributable to shareholders of the parent company was ¥2,117,720,554.70, up from ¥1,722,741,201.60 in the previous year, indicating a growth of 23.0%[34] Cash Flow - The net cash flow from operating activities for the year-to-date period was ¥179,311,770.70, an increase of 83.54% compared to ¥97,923,313.84 in the previous year[11] - Cash inflow from operating activities totaled CNY 2,387,699,580.80, compared to CNY 2,337,675,211.89 in the previous period[42] - Cash outflow from operating activities was CNY 2,208,387,810.10, down from CNY 2,239,977,390.36 in the previous period[46] - Net cash flow from investing activities was CNY -249,957,842.42, an improvement from CNY -460,377,615.01 in the previous period[46] - Cash inflow from financing activities was CNY 1,394,531,300.00, compared to CNY 221,226,636.00 in the previous period[46] - Net cash flow from financing activities was CNY 104,954,507.18, a significant recovery from CNY -1,037,090,264.24 in the previous period[46] Shareholder Information - Total number of common shareholders at the end of the reporting period is 36,448[24] - The largest shareholder, Beijing New Mile Health Industry Group Co., Ltd., holds 24.42% of shares, totaling 825,927,323 shares[24] - The company has a total of 10 major shareholders, with the third-largest being Wukuang Jintong Equity Investment Fund Management Co., Ltd., holding 10.83%[24] - The total number of shares held by the top 10 unrestricted shareholders is 1,366,000,000 shares[24] - The company does not have any preferred shareholders or related financing activities among the top 10 shareholders[27] Operational Changes - The company reported a significant increase in accounts receivable, which rose by 31.48% to ¥992,394,752.36 due to the addition of newly consolidated subsidiaries and an increase in medical insurance receivables[15] - The company experienced a 37.59% increase in inventory, reaching ¥228,794,806.61, attributed to the consolidation of new subsidiaries[15] - Total short-term borrowings increased by 130.77% to ¥725,228,609.78 due to new subsidiaries and additional bank loans[18] - Long-term borrowings increased by 84.68% to ¥758,104,335.75, attributed to new subsidiaries and additional bank loans[18] - Management expenses increased by 44.11% to ¥440,128,431.58, primarily due to the amortization of equity incentive costs[18] - The company reported a significant decline in investment income, down 92.49% to ¥868,969.99, compared to the same period last year[18] Research and Development - Research and development expenses rose to ¥6,905,702.82, marking a 100% increase compared to the previous period[18] - Research and development expenses for the period were ¥6,905,702.82, reflecting the company's commitment to innovation[38] Strategic Initiatives - The company is focused on expanding its market presence and developing new products and technologies[30] - The company is exploring potential mergers and acquisitions to enhance its market position[30]